| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/19/2004 | WO2004014147A1 Method for controlling hairballs |
| 02/19/2004 | WO2004007726A3 Brachyspira hyodysenteriae vaccine |
| 02/19/2004 | WO2004007481A3 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 02/19/2004 | WO2004007478A3 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 02/19/2004 | WO2004000840A3 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 02/19/2004 | WO2004000312A3 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins |
| 02/19/2004 | WO2003104473A3 Galactosyl isomalt, method for production and use thereof |
| 02/19/2004 | WO2003086306A3 5ht2c receptor modulators |
| 02/19/2004 | WO2003082190A3 Spirocyclic amides as cannabinoid receptor modulators |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065989A3 (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003053474A3 Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 02/19/2004 | WO2003052051A3 Adeno-associated virus (aav) serotype 8 sequences |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003045411A3 Ginger extract preparation |
| 02/19/2004 | WO2003043639A3 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER |
| 02/19/2004 | WO2003027234A9 Small organic molecule regulators of cell proliferation |
| 02/19/2004 | WO2003025014A3 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 02/19/2004 | WO2003024402A3 Lpa receptor agonists and antagonists and methods of use |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2002074251A3 Monoclonal antibody therapy for pancreas cancer |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002061086A3 Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1 |
| 02/19/2004 | WO2002056895A3 Ionene polymers and their use in treating mucositis |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002042328A3 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034218 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 02/19/2004 | US20040034102 Oral pediatric trimethobenzamide formulations and methods |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034089 Such as (1-((2,3-dihydro-2-(4-propyl-1H-imidazol-2-yl)-1H-indol-1 -yl)carbonyl)propyl)-carbamate; for inactivation of cholecystokinins |
| 02/19/2004 | US20040034076 Such as methyl-3-azido-2-((4,6-dimethoxy-2-pyrimidinyl)oxy) 3,3-diphenylpropionate; for treatment of high blood pressure |
| 02/19/2004 | US20040034070 Propanolaminotetralines, preparation thereof and compositions containing same |
| 02/19/2004 | US20040034066 Rosiglitazone hydrochloride is stable, water solubility, high melting point, bulk flow and good for bulk preparation and handling; salt formation |
| 02/19/2004 | US20040034065 A mixture of valsartan, an insulin secretion enhancer or a insulin sensitizer, for treating hypertension, congestive heart failure, diabetes, type 2 diabetes, renal failure, premenstrual syndrome, coronary heart disease |
| 02/19/2004 | US20040034061 An antagonist of corticotropin releasing factor receptor, treating depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disorders, drug dependence |
| 02/19/2004 | US20040034055 For treating central nervous system disorders, immunomodulatory disorders, antimalaria, viral disease of Borna virus, Hepatitis; a 6-azatricyclo(6.3.1.01,6)dodecane derivatives |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034041 Novel anti-infectives |
| 02/19/2004 | US20040034040 E.g., 5-(4-(3-chloro-4-methoxybenzylamino)-5,6,7,8-tetra-hydro-1-benzothieno(2,3 -d) pyrimidin-2-yl)valeric acid to treat high pullmonary pressure; hypotensive agents; liver, cardiovascular, kidney and sexual disorders; antiallergens |
| 02/19/2004 | US20040034028 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034020 A purine deriveative, useful for treatment of inflammatory conditions, immune disorders, tissue injury, infections, and cancer |
| 02/19/2004 | US20040034018 2-amino-trihydroindole or tetrahydronapthalene-2-yl derivatives, useful for disease state associated with smooth muscle disorders, such as gastrointestinal and urogenital disorders |
| 02/19/2004 | US20040034015 Administering to a human patient suffering from addictive behavior associated with 5HT2C receptor modulation, a fused tetra or pentaheterocyclic compound containing nitrogen in the rings |
| 02/19/2004 | US20040034012 Superior arginine vasopressin receptor antagonism; a 6-membered aromatic ring having nitrogen at the 2-position there of is substituted at 2 position of the imidazobenzazepine ring |
| 02/19/2004 | US20040034005 Administering to a patient suffering from psychological disoders a (1,4)diazocino(7,7,1-hi)inodle derivative as 5HT2c agonist or partial agonist |
| 02/19/2004 | US20040033995 Nitrogen compounds, stereoisomers and/or racemic mixtures used as enzyme inhibitors for prophylaxis of inflammatory diseases |
| 02/19/2004 | US20040033994 Use of compounds comprising a nitrogen-oxygen heterocycle |
| 02/19/2004 | US20040033986 Anti tubercular drug: compositions and methods |
| 02/19/2004 | US20040033983 Dietetic mixtures comprising polyglucomannans, excipients and lipase inhibitors such as orlistat |
| 02/19/2004 | US20040033977 Oligonucleotide modulation of cell adhesion |
| 02/19/2004 | US20040033952 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033951 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033946 Cell damage inhibitor |
| 02/19/2004 | US20040033593 Bioartificial device for the storage, cultivation and/or multiplication of cells |
| 02/19/2004 | US20040033520 Diagnosing metastatic colorectal, stomach and/or esophageal cancer in vitro; immunoassay; radioimaging tumors; immunotherapeutics; genetic vaccines |
| 02/19/2004 | US20040033231 First domain comprising a PP14 polypeptide sequence and a second domain comprising a polypeptide sequence of the Fc region of an immunoglobulin protein; treatment of immune system diseases and disorders |
| 02/19/2004 | US20040033220 Use of enzymes obtained from ciliates as medicaments for promoting digestion |
| 02/19/2004 | US20040033215 Transferring a cell proliferation factor gene into a mammalian liver cell, for an in vitro immortalized cell, proliferating the immortalized cell, and removing the cell proliferation factor gene |
| 02/19/2004 | US20040033211 Antigen arrays for treatment of bone disease |
| 02/19/2004 | US20040033200 Modified FVII in treatment of ARDS |
| 02/19/2004 | DE19930030B4 CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform CO-3 unsaturated fatty acids containing oral dosage form |
| 02/19/2004 | DE19860373B4 Mundpflegemittel und Verwendung von sphärischen Mikropartikeln The oral care composition and use of spherical microparticles |
| 02/19/2004 | CA2497658A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2497448A1 Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494742A1 Tiacumicin production |
| 02/19/2004 | CA2494298A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | CA2494192A1 Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493143A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 02/18/2004 | EP1389619A1 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/18/2004 | EP1389616A1 Novel benzylpiperidine compound |
| 02/18/2004 | EP1389466A1 Immunopotentiators |
| 02/18/2004 | EP1389464A1 Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same |
| 02/18/2004 | EP1389233A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/18/2004 | EP1389207A1 Polymorphic and other crystalline forms of cis-ftc |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389204A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same |
| 02/18/2004 | EP1389202A1 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 02/18/2004 | EP1389201A1 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/18/2004 | EP1389200A1 Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors |
| 02/18/2004 | EP1389181A2 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/18/2004 | EP1389116A1 Cathartic composition |
| 02/18/2004 | EP1389112A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/18/2004 | EP1389110A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 02/18/2004 | EP1389109A1 Gastric acid secretion inhibiting composition |
| 02/18/2004 | EP1389108A2 Methods for selective immunomodulation using pimecrolimus |
| 02/18/2004 | EP1389107A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
| 02/18/2004 | EP1389044A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
| 02/18/2004 | EP1325001B1 Anticholinergic agents that can be used as medicaments and method for the production thereof |
| 02/18/2004 | EP1292572B1 Propanolaminotetralines, preparation thereof and compositions containing same |